Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
-
One-Shot eye injection aims to halt rare genetic vision loss
Disease control Recruiting nowThis early-stage study is testing a one-time gene therapy injection for two rare, inherited eye diseases that cause progressive vision loss: Best vitelliform macular dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). Researchers will give the experimental drug, OPGx…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Doctors test One-Shot gene injection to fight rare blindness
Disease control Recruiting nowThis study is testing a new gene therapy called OPGx-001 for people with LCA5, a rare genetic condition that damages the retina and leads to vision loss. A small number of participants will receive an injection of the therapy into one eye to see if it is safe and if it might help…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC